Article

Carolyn Presley on the Implications of Screening on Lung Cancer Care

Author(s):

Carolyn Presley

Carolyn Presley discusses the implications of screening on diagnosis and treatment of lung cancer.

Carolyn Presley, clinical fellow, geriatric oncology, Yale Cancer Center, Robert Wood Johnson Clinical Scholar, discusses the implications of screening on diagnosis and treatment of lung cancer.

Read more about the study.

Related Videos
Image of man with brown hair.
Image of woman with blonde hair.
Image of a woman with brown shoulder-length hair, wearing a khaki colored blazer.
Image of a man wearing a black button-up shirt.
Image of man with black hair.
Image of a man with dark hair and some facial hair.
Image of a man with blond facial hair.
Image of woman with blonde hair.
Image of a woman with long red hair.
Related Content
‘Too Young For Cancer’ Author on the Importance of Advocating for Yourself
December 5th 2024

‘Too Young For Cancer’ Author on the Importance of Advocating for Yourself

Alex Biese
Author and kidney cancer survivor Katie Coleman explains why patients with cancer need to advocate for themselves when navigating the medical system.
CURE Cancer Horizons logo
February 26th 2024

FDA Approvals from February 2024

Alex Biese Brielle Benyon
February brought in multiple FDA approvals in the oncology space. Here’s an overview of some of the most recent ones.
"FDA" text.
December 4th 2024

FDA Approves Bizengri for Some with NSCLC, Pancreatic Adenocarcinoma

Alex Biese
The FDA has approved the first systemic therapy for patients with NSCLC or pancreatic adenocarcinoma with an NRG1 gene fusion.
Guidelines for Childhood Neuroblastoma, FDA Decisions and More
February 12th 2024

Guidelines for Childhood Neuroblastoma, FDA Decisions and More

Alex Biese Brielle Benyon
Last week, we saw a few moving parts in the regulatory space, from new NCCN guidelines for pediatric neuroblastoma treatment to FDA Fast Tracks and Priority Reviews
Image of FDA Breakthrough Therapy Designation on a gold background.
December 3rd 2024

FDA Grants Breakthrough Therapy Designation to Sac-TMT for Some with NSCLC

Alex Biese
The FDA has granted Breakthrough Therapy designation to sacituzumab tirumotecan for patients with advanced or metastatic nonsquamous NSCLC with EGFR mutations.
Illustration of a person holding a magnifying glass next to paperwork and pills.
December 3rd 2024

Nemvaleukin Shows Manageable Safety Profile in Advanced Solid Tumors

Ashley Chan
In patients with advanced solid tumors, treatment with nemvaleukin with or without Keytruda demonstrated antitumor activity and tolerability.